Literature DB >> 24079473

MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.

Gabriella Aquino1, Laura Marra1, Monica Cantile1, Annarosaria De Chiara1, Giuseppina Liguori1, Maria Pia Curcio1, Rocco Sabatino1, Giuseppe Pannone2, Antonio Pinto3, Gerardo Botti1, Renato Franco1.   

Abstract

Myc oncogenetic deregulation is abundantly described in several solid human cancer and lymphomas. Particularly, Burkitt's lymphoma belongs to the family of B Non Hodgkin aggressive lymphomas. Although it is morphologically characterized, immunophenotypic and cytogenetic diagnosis remains complex. In 2008, the WHO has introduced a new diagnostic class of aggressive B-cell lymphomas with features intermediate between BL and DLBCL. This diagnostic class represents a temporary container of aggressive B-cell lymphomas, not completely belonging to the BL and DLBCL categories. The importance of establishing a correct diagnosis would allow a better prognostic classification and a better therapeutic approach. In this review, we summarize the main diagnostic approaches necessary for appropriate diagnoses and we emphasize the importance of cytogenetic analysis of the oncogene Myc in the histopathological diagnosis and the prognostic/predictive stratification. In this contest, Myc represents the more involved gene in the development of these lymphomas. Therefore, we analyze the genetic aberrations causing its over-expression and the concomitant deregulation of molecular pathways related to it. We also propose a FISH approach useful in the diagnosis of these lymphomas.

Entities:  

Year:  2013        PMID: 24079473      PMCID: PMC3850004          DOI: 10.1186/1750-9378-8-37

Source DB:  PubMed          Journal:  Infect Agent Cancer        ISSN: 1750-9378            Impact factor:   2.965


  62 in total

1.  Transcriptional analysis of the B cell germinal center reaction.

Authors:  Ulf Klein; Yuhai Tu; Gustavo A Stolovitzky; Jeffrey L Keller; Joseph Haddad; Vladan Miljkovic; Giorgio Cattoretti; Andrea Califano; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

3.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

4.  Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Pei Lin; Timothy J Dickason; Luis E Fayad; Patrick A Lennon; Peter Hu; Mar Garcia; Mark J Routbort; Roberto Miranda; Xumei Wang; Wei Qiao; L Jeffrey Medeiros
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

Review 5.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

6.  Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors.

Authors:  C Cinti; P P Claudio; C M Howard; L M Neri; Y Fu; L Leoncini; G M Tosi; N M Maraldi; A Giordano
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.

Authors:  Saloua Toujani; Philippe Dessen; Nathalie Ithzar; Gisèle Danglot; Catherine Richon; Yegor Vassetzky; Thomas Robert; Vladimir Lazar; Jacques Bosq; Lydie Da Costa; Christine Pérot; Vincent Ribrag; Catherine Patte; Jöelle Wiels; Alain Bernheim
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

8.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  H A Poirel; M S Cairo; N A Heerema; J Swansbury; A Aupérin; E Launay; W G Sanger; P Talley; S L Perkins; M Raphaël; K McCarthy; R Sposto; M Gerrard; A Bernheim; C Patte
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

View more
  6 in total

1.  Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.

Authors:  Kavita S Subramaniam; Intan Sofia Omar; Soke Chee Kwong; Zahurin Mohamed; Yin Ling Woo; Noor Azmi Mat Adenan; Ivy Chung
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

2.  MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Kamraan Z Gill; Fabio Iwamoto; Ashleigh Allen; Daniela Hoehn; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

Review 3.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Authors:  Qingqing Cai; L Jeffrey Medeiros; Xiaolu Xu; Ken H Young
Journal:  Oncotarget       Date:  2015-11-17

4.  A modular transcriptome map of mature B cell lymphomas.

Authors:  Henry Loeffler-Wirth; Markus Kreuz; Lydia Hopp; Arsen Arakelyan; Andrea Haake; Sergio B Cogliatti; Alfred C Feller; Martin-Leo Hansmann; Dido Lenze; Peter Möller; Hans Konrad Müller-Hermelink; Erik Fortenbacher; Edith Willscher; German Ott; Andreas Rosenwald; Christiane Pott; Carsten Schwaenen; Heiko Trautmann; Swen Wessendorf; Harald Stein; Monika Szczepanowski; Lorenz Trümper; Michael Hummel; Wolfram Klapper; Reiner Siebert; Markus Loeffler; Hans Binder
Journal:  Genome Med       Date:  2019-04-30       Impact factor: 11.117

5.  Gastric Burkitt lymphoma: A case report and literature review.

Authors:  Simona Gurzu; Tivadar Bara; Tivadar Jr Bara; Mihai Turcu; Ciprian Valentin Mardare; Ioan Jung
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human.

Authors:  Anthony B Eason; Sang-Hoon Sin; Carolina Lin; Blossom Damania; Steven Park; Yuri Fedoriw; Carlos E Bacchi; Dirk P Dittmer
Journal:  Oncotarget       Date:  2016-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.